WCLC News

Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.

While ultimately underpowered, Dr. Giulia Pasello said combination therapy demonstrated an improvement in median PFS compared to chemotherapy alone.

Motoko Tachihara, MD, PhD, addresses various treatment strategies for SCLC populations in an interview with ILCN.

Leading experts will outline how genomics, AI, and surgical technology are shaping the next generation of thoracic oncology.

During the session, Drs. Arsela Prelaj, Victor Velculescu, and Lars Konge will address topics that promise to shape the future of thoracic oncology.

Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.

Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.

In addition to recent developments in lung cancer care, attendees will hear from outgoing IASLC President Dr. Paul Van Schil and incoming President Dr. Caicun Zhou.

Investigators Wenfeng Fang, MD, PhD, and Fei Zhou, MD, PhD, share results from mono, combination studies of iza-bren. The data will be discussed during an oral abstract session Monday afternoon.

In a Q&A with ILCN, Gisele Fraga Moreira discusses the role of targeted therapies in lung cancer care and managing toxicities with new treatments.